WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer J.C. Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed rule, we stand ready to work with the Administration to achieve our shared goal
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer J.C. Scott released the following statement on the Department of Health and Human Services’ proposal requiring drug companies to disclose the list price of prescription drugs in television ads: “We share the Administration’s goal of reducing prescription drug prices. Pharmacy benefit managers (PBMs) foster competition among drugmakers, resulting
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) released the following statement on President Trump signing into law S. 2553/ S. 2554, the Know the Lowest Price Act of 2018 and the Patient Right to Know Drug Prices Act. “PCMA strongly supports S. 2553 and S. 2554, legislation that will help ensure America’s patients always pay the lowest cost for their medications at
WASHINGTON — Today, the U.S. House of Representatives passed the SUPPORT for Patients and Communities Act (H.R. 6), which will require electronic prescribing (e-prescribing) for controlled substances in Medicare. This is a significant step in the fight against America’s opioid epidemic, the Pharmaceutical Care Management Association (PCMA) said. “This will save lives and reduce fraud by
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on S. 2554, the Patient Right to Know Drug Prices Act, scheduled to be marked up tomorrow in the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP): “PCMA strongly supports S. 2554, legislation that will ensure America’s
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on the Food and Drug Administration’s (FDA) new Biosimilars Action Plan: “We applaud the FDA for taking important steps toward approving more biosimilars in the United States. We are encouraged the FDA has designed a system that allows manufacturers
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement today on the Administration’s Blueprint on drug pricing: “We are encouraged that the Administration’s Blueprint raises several proposals that would increase the use of pharmacy benefit management (PBM) tools to reduce costs in public programs. We support using PBM tools
